[Cardicap treatment of ischemic heart disease in aged patients].
The paper presents the results obtained in the study of efficacy of a new antianginal drug cardicap, a long acting isosorbide dinitrate (Natko, India). Changes in the clinical symptoms, exercise tolerance, ECG monitoring and echo-CG parameters in 27 patients (mean age 63 years) with ischemic heart disease, class II and III angina pectoris enable the conclusion on marked antianginal, vasodilatating effect of cardicap, on a rise in the exercise tolerance, reduction in the myocardial power consumption. The effect of cardicap was time-related.